サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1504160

モノクローナル抗体の市場規模、シェア、予測、動向分析：製品タイプ、用途、供給源、生産、エンドユーザー別 - 2031年までの世界予測

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type Application, Source, Production, End User - Global Forecast to 2031

出版日
ページ情報
英文 410 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.00円
モノクローナル抗体の市場規模、シェア、予測、動向分析：製品タイプ、用途、供給源、生産、エンドユーザー別 - 2031年までの世界予測
出版日: 2024年06月01日
発行: Meticulous Research
ページ情報: 英文 410 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のモノクローナル抗体市場は、2024年から2031年までのCAGR11.2%で、2031年までに4,498億米ドルに達すると予測されます。

モノクローナル抗体市場規模、シェア、予測、動向分析：製品タイプ（治療、研究、診断）用途（腫瘍学、免疫学、心臓病学、神経学）、供給源（ヒト化、マウス、ヒト）、生産、エンドユーザー別-2031年までの世界予測

本レポートは、モノクローナル抗体市場シナリオの広範な2次調査と1次調査、および詳細な分析を経て、主要な業界促進要因、抑制要因、課題、および機会の分析から構成されています。モノクローナル抗体市場の成長は、世界のがんと自己免疫疾患の高負担、臨床試験と研究のための資金調達の増加、バイオ医薬品産業の成長、感染症の有病率の上昇、プロテオミクスとゲノミクスの研究の増加によって牽引されています。しかし、代替診断検査が利用可能であること、抗体開発に高いコストと時間がかかることが、市場の成長を抑制しています。

さらに、製薬企業やバイオテクノロジー企業による研究開発投資の増加、臨床試験や医学研究における抗体の応用拡大、新興国における研究活動の増加、新たなバイオマーカー同定のニーズの高まり、診断検査の強化を目的とした取り組みなどが、市場成長の機会を生み出すと期待されています。しかし、抗体検査の精度の低さ、製造コストの高さ、研究用抗体の品質と安定性に関する懸念、製造工程の複雑さなどが、市場の成長を阻害する課題となっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

  • 概要
  • 促進要因
    • 世界のがんと自己免疫疾患の高負担率
    • 臨床試験と研究のための資金調達の増加
    • バイオ医薬品産業の成長
    • プロテオミクスおよびゲノミクス研究の増加
    • 感染症の流行増加
  • 抑制要因
    • 代替診断検査の利用可能性
    • 抗体開発に要する高いコストと時間
  • 機会
    • 臨床試験や医学研究における抗体の応用拡大
    • 新興諸国における研究開発の活発化
    • 新たなバイオマーカー同定の必要性の高まり
    • 診断検査強化に向けた取り組み
    • 製薬・バイオテクノロジー企業による研究開発投資の増加
  • 課題
    • 抗体検査の精度の低さ
    • 高い製造コスト
    • 調査用抗体の品質と安定性に関する懸念
    • 製造工程の複雑さ
  • 要因分析
  • 動向
    • 個別化医療への関心の高まり
    • 抗体工学の進歩
    • モノクローナル抗体生産における人工知能の統合
    • ヒト化マウスモデルの使用
  • 規制分析
  • 価格分析
  • パイプライン分析
  • ポーターのファイブフォース分析

第5章 モノクローナル抗体市場：タイプ別評価

  • 概要
  • 研究用モノクローナル抗体
    • 調査領域
      • 腫瘍学
      • 感染症
      • 循環器学
      • 免疫学
      • 神経学
      • 幹細胞研究
      • その他の研究分野
    • 応用分野
      • プロテオミクス
      • 創薬・医薬品開発
      • ゲノミクス
    • テクノロジー
      • フローサイトメトリー
      • 免疫蛍光法
      • 酵素結合免疫吸着測定法
      • マルチプレックス免疫吸着アッセイ
      • ウェスタンブロット
      • 免疫組織化学
      • 免疫沈降（IP）
      • その他の調査技術
  • 診断用モノクローナル抗体
    • 用途
      • 腫瘍学
      • 感染症
      • 妊娠検出／不妊検査
      • 心臓マーカー検査
      • その他の診断用途
    • テクノロジー
      • ELISA法
      • ラテラルフローアッセイ
      • 免疫組織化学（IHC）
      • 免疫沈降（IP）
      • ウェスタンブロット（WB）
      • 免疫細胞化学（ICC）
      • その他の診断技術
  • 治療用モノクローナル抗体
    • 治療領域
      • 腫瘍学
      • 自己免疫疾患
      • 神経疾患
      • 感染症
      • その他の治療領域
    • 投与経路
      • 皮下
      • 静脈内投与

第6章 モノクローナル抗体市場：製造プロセス別評価

  • 概要
  • In Vivoプロセス
  • In Vitroプロセス
    • アップストリームプロセス
    • ダウンストリームプロセス

第7章 モノクローナル抗体市場：供給源別評価

  • 概要
  • ヒト
  • ヒト化
  • マウス
  • キメラ
  • その他の供給源

第8章 モノクローナル抗体市場：エンドユーザー別評価

  • 概要
  • 製薬・バイオテクノロジー企業
  • 病院
  • CRO（医薬品開発業務受託機関）
  • その他のエンドユーザー

第9章 モノクローナル抗体市場：地域別評価

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • スイス
    • ベルギー
    • その他欧州（RoE）
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • その他アジア太平洋地域（RoAPAC）
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ（RoLATAM）
  • 中東・アフリカ

第10章 競合分析

  • 概要
  • 主要成長戦略
  • 競合ベンチマーキング
  • 競合ダッシュボード
    • 業界リーダー
    • 市場差別化要因
    • 先行企業
    • 新興企業
  • 主要企業別市場シェア分析／市場ランキング（2023年）

第11章 企業プロファイル（企業概要、財務概要、製品ポートフォリオ、戦略的展開、SWOT分析）

  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb
  • GSK plc
  • Merck KGaA
  • Eli Lilly and Company
  • AstraZeneca plc
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company
  • Biogen
  • Thermo Fisher Scientific Inc.

（注：上位5社のSWOT分析を掲載）

第12章 付録

図表

LIST OF TABLES

  • Table 1 Global Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 2 Global Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 3 Global Research Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Research Monoclonal Antibodies Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Research Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Global Research Monoclonal Antibodies Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 7 Global Research Monoclonal Antibodies Market for Immunology, by Country/Region, 2022-2031 (USD Million)
  • Table 8 Global Research Monoclonal Antibodies Market for Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Research Monoclonal Antibodies Market for Stem Cell Research, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Research Monoclonal Antibodies Market for Other Research Areas, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 12 Global Research Monoclonal Antibodies Market for Proteomics, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Research Monoclonal Antibodies Market for Drug Discovery & Development, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Research Monoclonal Antibodies Market for Genomics, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 16 Global Research Monoclonal Antibodies Market for Flow Cytometry, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Research Monoclonal Antibodies Market for Immunofluorescence, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Research Monoclonal Antibodies Market for Enzyme-Linked Immunosorbent Assay, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global Research Monoclonal Antibodies Market for Multiplex Immunosorbent Assay, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Research Monoclonal Antibodies Market for Western Blot, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Research Monoclonal Antibodies Market for Immunohistochemistry, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Research Monoclonal Antibodies Market for Immunoprecipitation (IP), by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Research Monoclonal Antibodies Market for Other Research Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 25 Global Diagnostic Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Diagnostic Monoclonal Antibodies Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Diagnostic Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Diagnostic Monoclonal Antibodies Market for Pregnancy Detection/Fertility Testing, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Diagnostic Monoclonal Antibodies Market for Cardiac Marker Testing, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Diagnostic Monoclonal Antibodies Market for Other Diagnostic Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 32 Global Diagnostic Monoclonal Antibodies Market for ELISA, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Diagnostic Monoclonal Antibodies Market for Lateral Flow Assay, by Country/Region, 2022-2031 (USD Million)
  • Table 34 Global Diagnostic Monoclonal Antibodies Market for Immunohistochemistry (IHC), by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Diagnostic Monoclonal Antibodies Market for Immunoprecipitation (IP), by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Diagnostic Monoclonal Antibodies Market for Western Blot (WB), by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Diagnostic Monoclonal Antibodies Market for Immunocytochemistry (ICC), by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Diagnostic Monoclonal Antibodies Market for Other Diagnostic Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 39 Global Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 40 Global Therapeutic Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 41 Global Therapeutic Monoclonal Antibodies Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 42 Global Therapeutic Monoclonal Antibodies Market for Autoimmune Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 43 Global Therapeutic Monoclonal Antibodies Market for Neurological Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 44 Global Therapeutic Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 45 Global Therapeutic Monoclonal Antibodies Market for Other Therapeutic Areas, by Country/Region, 2022-2031 (USD Million)
  • Table 46 Global Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 47 Global Subcutaneous Therapeutic Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 48 Global Intravenous Therapeutic Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 49 Global Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 50 Global Monoclonal Antibodies Market for In Vivo Process, by Country/Region, 2022-2031 (USD Million)
  • Table 51 Global Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 52 Global Monoclonal Antibodies Market for In Vitro Process, by Country/Region, 2022-2031 (USD Million)
  • Table 53 Global Monoclonal Antibodies Market for Upstream Process, by Country/Region, 2022-2031 (USD Million)
  • Table 54 Global Monoclonal Antibodies Market for Downstream Process, by Country/Region, 2022-2031 (USD Million)
  • Table 55 Global Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 56 Global Human Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 57 Global Humanized Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 58 Global Murine Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Global Chimeric Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 60 Global Monoclonal Antibodies Market for Other Sources, by Country/Region, 2022-2031 (USD Million)
  • Table 61 Global Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 62 Global Monoclonal Antibodies Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 63 Global Monoclonal Antibodies Market for Hospitals, by Country/Region, 2022-2031 (USD Million)
  • Table 64 Global Monoclonal Antibodies Market for Contract Research Organizations, by Country/Region, 2022-2031 (USD Million)
  • Table 65 Global Monoclonal Antibodies Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 66 Global Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 67 North America: Monoclonal Antibodies Market, by Country, 2022-2031 (USD Million)
  • Table 68 North America: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 69 North America: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 70 North America: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 71 North America: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 72 North America: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 73 North America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 74 North America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 75 North America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 76 North America: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 77 North America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 78 North America: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 79 North America: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 80 U.S.: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 81 U.S.: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 82 U.S.: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 83 U.S.: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 84 U.S.: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 85 U.S.: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 86 U.S.: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 87 U.S.: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 88 U.S.: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 89 U.S.: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 90 U.S.: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 91 U.S.: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 92 Canada: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 93 Canada: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 94 Canada: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 95 Canada: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 96 Canada: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 97 Canada: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 98 Canada: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 99 Canada: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 100 Canada: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 101 Canada: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 102 Canada: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 103 Canada: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 104 Europe: Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 105 Europe: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 106 Europe: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 107 Europe: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 108 Europe: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 109 Europe: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 110 Europe: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 111 Europe: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 112 Europe: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 113 Europe: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 114 Europe: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 115 Europe: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 116 Europe: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 117 Germany: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 118 Germany: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 119 Germany: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 120 Germany: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 121 Germany: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 122 Germany: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 123 Germany: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 124 Germany: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 125 Germany: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 126 Germany: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 127 Germany: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 128 Germany: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 129 France: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 130 France: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 131 France: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 132 France: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 133 France: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 134 France: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 135 France: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 136 France: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 137 France: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 138 France: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 139 France: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 140 France: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 141 U.K.: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 142 U.K.: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 143 U.K.: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 144 U.K.: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 145 U.K.: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 146 U.K.: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 147 U.K.: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 148 U.K.: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 149 U.K.: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 150 U.K.: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 151 U.K.: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 152 U.K.: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 153 Italy: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 154 Italy: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 155 Italy: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 156 Italy: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 157 Italy: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 158 Italy: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 159 Italy: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 160 Italy: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 161 Italy: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 162 Italy: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 163 Italy: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 164 Italy: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 165 Spain: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 166 Spain: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 167 Spain: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 168 Spain: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 169 Spain: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 170 Spain: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 171 Spain: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 172 Spain: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 173 Spain: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 174 Spain: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 175 Spain: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 176 Spain: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 177 Switzerland: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 178 Switzerland: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 179 Switzerland: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 180 Switzerland: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 181 Switzerland: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 182 Switzerland: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 183 Switzerland: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 184 Switzerland: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 185 Switzerland: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 186 Switzerland: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 187 Switzerland: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 188 Switzerland: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 189 Belgium: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 190 Belgium: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 191 Belgium: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 192 Belgium: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 193 Belgium: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 194 Belgium: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 195 Belgium: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 196 Belgium: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 197 Belgium: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 198 Belgium: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 199 Belgium: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 200 Belgium: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 201 Rest of Europe: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 202 Rest of Europe: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 203 Rest of Europe: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 204 Rest of Europe: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 205 Rest of Europe: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 206 Rest of Europe: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 207 Rest of Europe: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 208 Rest of Europe: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 209 Rest of Europe: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 210 Rest of Europe: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 211 Rest of Europe: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 212 Rest of Europe: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 213 Asia-Pacific: Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 214 Asia-Pacific: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 215 Asia-Pacific: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 216 Asia-Pacific: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 217 Asia-Pacific: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 218 Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 219 Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 220 Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 221 Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 222 Asia-Pacific: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 223 Asia-Pacific: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 224 Asia-Pacific: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 225 Asia-Pacific: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 226 China: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 227 China: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 228 China: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 229 China: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 230 China: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 231 China: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 232 China: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 233 China: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 234 China: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 235 China: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 236 China: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 237 China: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 238 Japan: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 239 Japan: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 240 Japan: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 241 Japan: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 242 Japan: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 243 Japan: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 244 Japan: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 245 Japan: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 246 Japan: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 247 Japan: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 248 Japan: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 249 Japan: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 250 India: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 251 India: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 252 India: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 253 India: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 254 India: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 255 India: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 256 India: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 257 India: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 258 India: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 259 India: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 260 India: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 261 India: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 262 South Korea: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 263 South Korea: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 264 South Korea: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 265 South Korea: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 266 South Korea: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 267 South Korea: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 268 South Korea: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 269 South Korea: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 270 South Korea: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 271 South Korea: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 272 South Korea: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 273 South Korea: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 274 Australia: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 275 Australia: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 276 Australia: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 277 Australia: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 278 Australia: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 279 Australia: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 280 Australia: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 281 Australia: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 282 Australia: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 283 Australia: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 284 Australia: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 285 Australia: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 286 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 287 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 288 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 289 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 290 Rest of Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 291 Rest of Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 292 Rest of Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 293 Rest of Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 294 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 295 Rest of Asia-Pacific: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 296 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 297 Rest of Asia-Pacific: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 298 Latin America: Monoclonal Antibodies Market, by Country/Region, 2022-2031 (USD Million)
  • Table 299 Latin America: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 300 Latin America: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 301 Latin America: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 302 Latin America: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 303 Latin America: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 304 Latin America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 305 Latin America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 306 Latin America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 307 Latin America: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 308 Latin America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 309 Latin America: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 310 Latin America: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 311 Brazil: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 312 Brazil: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 313 Brazil: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 314 Brazil: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 315 Brazil: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 316 Brazil: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 317 Brazil: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 318 Brazil: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 319 Brazil: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 320 Brazil: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 321 Brazil: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 322 Brazil: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 323 Mexico: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 324 Mexico: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 325 Mexico: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 326 Mexico: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 327 Mexico: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 328 Mexico: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 329 Mexico: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 330 Mexico: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 331 Mexico: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 332 Mexico: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 333 Mexico: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 334 Mexico: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 335 Rest of Latin America: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 336 Rest of Latin America: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 337 Rest of Latin America: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 338 Rest of Latin America: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 339 Rest of Latin America: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 340 Rest of Latin America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 341 Rest of Latin America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 342 Rest of Latin America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 343 Rest of Latin America: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 344 Rest of Latin America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 345 Rest of Latin America: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 346 Rest of Latin America: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 347 Middle East & Africa: Monoclonal Antibodies Market, by Type, 2022-2031 (USD Million)
  • Table 348 Middle East & Africa: Research Monoclonal Antibodies Market, by Research Area, 2022-2031 (USD Million)
  • Table 349 Middle East & Africa: Research Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 350 Middle East & Africa: Research Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 351 Middle East & Africa: Diagnostic Monoclonal Antibodies Market, by Application, 2022-2031 (USD Million)
  • Table 352 Middle East & Africa: Diagnostic Monoclonal Antibodies Market, by Technology, 2022-2031 (USD Million)
  • Table 353 Middle East & Africa: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 354 Middle East & Africa: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 355 Middle East & Africa: Monoclonal Antibodies Market, by Production Process, 2022-2031 (USD Million)
  • Table 356 Middle East & Africa: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022-2031 (USD Million)
  • Table 357 Middle East & Africa: Monoclonal Antibodies Market, by Source, 2022-2031 (USD Million)
  • Table 358 Middle East & Africa: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 359 Recent Developments, by Company, 2020-2024
  • Table 360 Middle East & Africa: Monoclonal Antibodies Market, by End User, 2022-2031 (USD Million)
  • Table 361 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global Monoclonal Antibodies Market, by Type, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Monoclonal Antibodies Market, by Production Process, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Monoclonal Antibodies Market, by Source, 2024 VS. 2031 (USD Million)
  • Figure 10 Global Monoclonal Antibodies Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 11 Global Monoclonal Antibodies Market, by Geography
  • Figure 12 Global Monoclonal Antibodies Market, by Type, 2024 VS. 2031 (USD Million)
  • Figure 13 Global Monoclonal Antibodies Market, by Production Process, 2024 VS. 2031 (USD Million)
  • Figure 14 Global Monoclonal Antibodies Market, by Source, 2024 VS. 2031 (USD Million)
  • Figure 15 Global Monoclonal Antibodies Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 16 Global Monoclonal Antibodies Market, by Geography, 2024 VS. 2031 (USD Million)
  • Figure 17 North America: Monoclonal Antibodies Market Snapshot
  • Figure 18 Europe: Monoclonal Antibodies Market Snapshot
  • Figure 19 Asia-Pacific: Monoclonal Antibodies Market Snapshot
  • Figure 20 Key Growth Strategies Adopted by Leading Players, 2020-2024
  • Figure 21 Global Monoclonal Antibodies Market: Competitive Benchmarking, by Type
  • Figure 22 Global Monoclonal Antibodies Market: Competitive Benchmarking, by Geography
  • Figure 23 Global Monoclonal Antibodies Market: Competitive Dashboard
  • Figure 24 Global Monoclonal Antibodies Market: Market Share Analysis/Market Ranking, By Key Players (2023)
  • Figure 25 Novartis AG: Financial Snapshot (2023)
  • Figure 26 Pfizer Inc.: Financial Snapshot (2023)
  • Figure 27 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
  • Figure 28 AbbVie Inc.: Financial Snapshot (2023)
  • Figure 29 Amgen Inc.: Financial Snapshot (2023)
  • Figure 30 Bristol-Myers Squibb: Financial Snapshot (2023)
  • Figure 31 GSK plc: Financial Snapshot (2023)
  • Figure 32 Merck KGaA: Financial Snapshot (2023)
  • Figure 33 Eli Lilly and Company: Financial Snapshot (2023)
  • Figure 34 AstraZeneca plc: Financial Snapshot (2023)
  • Figure 35 Johnson & Johnson: Financial Snapshot (2023)
  • Figure 36 Takeda Pharmaceutical Company Limited: Financial Snapshot (2023)
  • Figure 37 Daiichi Sankyo Company: Financial Snapshot (2023)
  • Figure 38 Biogen: Financial Snapshot (2023)
  • Figure 39 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
目次
Product Code: MRHC - 1041246

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User-Global Forecast to 2031

The global monoclonal antibodies market is projected to reach $449.8 billion by 2031 at a CAGR of 11.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the monoclonal antibodies market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the monoclonal antibodies market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market's growth.

Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market's growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of over 90.2% of the monoclonal antibodies market. The therapeutic monoclonal antibodies segment is further sub-segmented into oncology, autoimmune diseases, neurological diseases, infectious diseases, and other therapeutic areas. The large market share of this segment is attributed to the increasing approvals for the therapeutical monoclonal antibodies, rising demand for biosimilars, increasing prevalence of target disease, technological advancements in the formulation of antibodies, an increasing number of pipeline products, and fewer side effects of monoclonal antibodies. Additionally, with the increasing prevalence of cancer, the demand for monoclonal antibodies is also increasing for personalized cancer therapies. According to GLOBOCAN, the prevalence of cancer is expected to increase by 63.4% in 2045 from 2022.

Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. The in vitro segment is further segmented into upstream process and downstream process. The in vitro process scales up antibody production without reliance on animal models and animal testing. It increases the production of MABs and also mitigates the ethical concerns associated with the use of animals, thus preferred over the in vivo process.

Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of the monoclonal antibodies market. Human sources are preferred for the production of monoclonal antibodies to increase treatment efficiency by reducing the risk of immunogenicity or adverse immune response. Key players are also using human sources for the development of monoclonal antibodies to improve the safety profile of MABs, production of stable human hybridomas, and ease of scaling up production.

Among the end users covered in this report, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. The large market share of this segment is attributed to the availability of MAB therapies in hospitals, the increasing number of hospitals in emerging economies, and the launch of dedicated monoclonal antibody facilities by hospitals.

An in-depth analysis of the geographical scenario of the global monoclonal antibodies market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of over 34.9% of the monoclonal antibodies market. The largest share of the regional market is attributed to the presence of key players, availability of advanced antibody engineering technology, rising number of approvals, and supportive government initiatives for the development and use of monoclonal antibodies. For instance, in September 2023, the U.S. Department of Health and Human Services announced an initiative to give underinsured and uninsured Americans access to the COVID-19 monoclonal antibody treatment bebtelovimab even after the product availability in the commercial market.

Scope of the Report:

Monoclonal Antibodies Market Assessment-by Type

  • Research Monoclonal Antibodies
    • Research Area
  • Oncology
  • Infectious Diseases
  • Cardiology
  • Immunology
  • Neurology
  • Stem Cell Research
  • Other Research Areas
    • Application
  • Proteomics
  • Drug Discovery & Development
  • Genomics
    • Technology
  • Flow Cytometry
  • Immunofluorescence
  • Enzyme-Linked Immunosorbent Assay
  • Multiplex Immunosorbent Assay
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation (IP)
  • Other Research Technologies
  • Diagnostic Monoclonal Antibodies
    • Application
  • Oncology
  • Infectious Diseases
  • Pregnancy Detection/Fertility Testing
  • Cardiac Marker Testing
  • Other Diagnostic Applications
    • Technology
  • ELISA
  • Lateral Flow Assay
  • Immunohistochemistry (IHC)
  • Immunoprecipitation (IP)
  • Western Blot (WB)
  • Immunocytochemistry (ICC)
  • Other Diagnostic Technologies
  • Therapeutic Monoclonal Antibodies
    • Therapeutic Area
  • Oncology
  • Autoimmune Diseases
  • Neurological Diseases
  • Infectious Diseases
  • Other Therapeutic Areas
    • Route of Administration
  • Subcutaneous
  • Intravenous

Note: 1) Other Research Areas include Ophthalmology and Rare Diseases

2) Other Research Technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay

3) Other Diagnostic Applications include Alzheimer's, autoimmune diseases, cardiac diseases, and diabetes.

4) Other Diagnostic Technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.

5) Other Therapeutic Areas include cardiac diseases, diabetes, ophthalmology, and hematology

Monoclonal Antibodies Market Assessment-by Production Process

  • In Vivo Process
  • In Vitro Process
    • Upstream Process
    • Downstream Process

Monoclonal Antibodies Market Assessment-by Source

  • Human
  • Humanized
  • Murine
  • Chimeric
  • Other Sources

Note: Other Sources include goat, sheep, chicken, and llama

Monoclonal Antibodies Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals
  • Contract Research Organizations
  • Other End Users

Note: Other End Users include academic & research institutes, nursing centers, and long-term care centers

Monoclonal Antibodies Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Switzerland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. High Burden of Cancer and Autoimmune Diseases Globally
    • 4.2.2. Increasing Funding for Clinical Trials and Research
    • 4.2.3. Growth in the Biopharmaceutical Industry
    • 4.2.4. Rising Proteomics and Genomics Research Studies
    • 4.2.5. Rising Prevalence of Infectious Diseases
  • 4.3. Restraints
    • 4.3.1. Availability of Alternative Diagnostic Tests
    • 4.3.2. High Costs & Time Required for Antibody Development
  • 4.4. Opportunities
    • 4.4.1. Expanding Applications of Antibodies in Clinical Trials and Medical Research
    • 4.4.2 Increasing Research Activities in Developing Countries
    • 4.4.3. Increasing Need for New Biomarker Identification
    • 4.4.4. Initiatives Aimed at Enhancing Diagnostic Testing
    • 4.4.5. Increasing R&D Investments by Pharmaceutical & Biotech Companies
  • 4.5. Challenges
    • 4.5.1. Inaccuracy of Antibody Tests
    • 4.5.2. High Manufacturing Costs
    • 4.5.3. Concerns Regarding the Quality & Stability of Research Antibodies
    • 4.5.4. Complexities in the Production Process
  • 4.6. Factor Analysis
  • 4.7. Trends
    • 4.7.1. Increasing Focus on Personalized Medicine
    • 4.7.2. Advancements in Antibody Engineering
    • 4.7.3. Integration of Artificial Intelligence in Monoclonal Antibody Production
    • 4.7.4. Use of Humanized Mouse Models
  • 4.8. Regulatory Analysis
  • 4.9. Pricing Analysis
  • 4.10. Pipeline Analysis
  • 4.11. Porter's Five Force Analysis

5. Monoclonal Antibodies Market Assessment-by Type

  • 5.1. Overview
  • 5.2. Research Monoclonal Antibodies
    • 5.2.1. Research Area
      • 5.2.1.1. Oncology
      • 5.2.1.2. Infectious Diseases
      • 5.2.1.3. Cardiology
      • 5.2.1.4. Immunology
      • 5.2.1.5. Neurology
      • 5.2.1.6. Stem Cell Research
      • 5.2.1.7. Other Research Areas
    • 5.2.2. Application
      • 5.2.2.1. Proteomics
      • 5.2.2.2. Drug Discovery & Development
      • 5.2.2.3. Genomics
    • 5.2.3. Technology
      • 5.2.3.1. Flow Cytometry
      • 5.2.3.2. Immunofluorescence
      • 5.2.3.3. Enzyme-Linked Immunosorbent Assay
      • 5.2.3.4. Multiplex Immunosorbent Assay
      • 5.2.3.5. Western Blot
      • 5.2.3.6. Immunohistochemistry
      • 5.2.3.7. Immunoprecipitation (IP)
      • 5.2.3.8. Other Research Technologies
  • 5.3. Diagnostic Monoclonal Antibodies
    • 5.3.1. Application
      • 5.3.1.1. Oncology
      • 5.3.1.2. Infectious Diseases
      • 5.3.1.3. Pregnancy Detection/Fertility Testing
      • 5.3.1.4. Cardiac Marker Testing
      • 5.3.1.5. Other Diagnostic Applications
    • 5.3.2. Technology
      • 5.3.2.1. ELISA
      • 5.3.2.2. Lateral Flow Assay
      • 5.3.2.3. Immunohistochemistry (IHC)
      • 5.3.2.4. Immunoprecipitation (IP)
      • 5.3.2.5. Western Blot (WB)
      • 5.3.2.6. Immunocytochemistry (ICC)
      • 5.3.2.7. Other Diagnostic Technologies
  • 5.4. Therapeutic Monoclonal Antibodies
    • 5.4.1. Therapeutic Area
      • 5.4.1.1. Oncology
      • 5.4.1.2. Autoimmune Diseases
      • 5.4.1.3. Neurological Diseases
      • 5.4.1.4. Infectious Diseases
      • 5.4.1.5. Other Therapeutic Areas
    • 5.4.2. Route of Administration
      • 5.4.2.1. Subcutaneous
      • 5.4.2.2. Intravenous

6. Monoclonal Antibodies Market Assessment-by Production Process

  • 6.1. Overview
  • 6.2. In Vivo Process
  • 6.3. In Vitro Process
    • 6.3.1. Upstream Process
    • 6.3.2. Downstream Process

7. Monoclonal Antibodies Market Assessment-by Source

  • 7.1. Overview
  • 7.2. Human
  • 7.3. Humanized
  • 7.4. Murine
  • 7.5. Chimeric
  • 7.6. Other Sources

8. Monoclonal Antibodies Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Pharmaceutical & Biotechnology Companies
  • 8.3. Hospitals
  • 8.4. Contract Research Organizations (CROs)
  • 8.5. Other End Users

9. Monoclonal Antibodies Market Assessment-by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Switzerland
    • 9.3.7. Belgium
    • 9.3.8. Rest of Europe (RoE)
  • 9.4. Asia-Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
    • 9.4.4. South Korea
    • 9.4.5. Rest of Asia-Pacific (RoAPAC)
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America (RoLATAM)
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis/Market Ranking, by Key Players (2023)

11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

  • 11.1. Novartis AG
  • 11.2. Pfizer Inc.
  • 11.3. F. Hoffmann-La Roche AG
  • 11.4. AbbVie Inc.
  • 11.5. Amgen Inc.
  • 11.6. Bristol-Myers Squibb
  • 11.7. GSK plc
  • 11.8. Merck KGaA
  • 11.9. Eli Lilly and Company
  • 11.10. AstraZeneca plc
  • 11.11 Johnson & Johnson
  • 11.12. Takeda Pharmaceutical Company Limited
  • 11.13. Daiichi Sankyo Company
  • 11.14. Biogen
  • 11.15. Thermo Fisher Scientific Inc.

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports